

INSTITUTE OF GLOBAL HEALTH INNOVATION









Artificial Intelligence in Mammography Study (AIMS)

Participant Information Leaflet


This NHS screening centre is taking part in a research study that is trialling a new technology that assists cancer specialists, and has the potential to improve NHS breast cancer screening. Our goal is to provide you and other women with an even better cancer screening service in the future.

This research aims to test the ability of a new computer system that uses a technology called artificial intelligence (AI) to help detect potential signs of cancer in the breast images (mammograms) that are taken during your screening visit. We have already completed a lot of research where we have shown that this technology is as good as an expert radiologist at identifying cancers on these scans. We believe that this technology has the potential to improve accuracy, safety, cost-effectiveness, and patient experience of breast screening in the UK. It may also have a role in supporting NHS screening services and clinicians directly. We now need to understand how it works in a real world NHS setting.

It's really important for you to know that this study will have <u>no</u> impact on your care, and the screening service will continue to run as normal. However, if you would prefer your images not to be included in the study, you may opt out of being part of this research (see details on the next page).

All scans, including yours, will be examined as normal by the cancer specialists at your screening centre, and these are the results that you will receive through the post following your visit. At the same time, in the background, your scans will also be read by the computer system, although results will be hidden from screening centre staff involved in your care.

The research team will not be able to see your name or any data that could identify you and all study data will remain confidential and will be stored securely.



This research has received NHS ethical approvals to include anonymised scans from all women attending this screening centre for the duration of the study. This means that your scans will be part of the study and will be read by the technology that we described earlier. We are really grateful for your participation in this study as it means we can include a representative population to test the technology rigorously. However, if you would prefer your images not to be included in the study, it is very easy to opt out of being part of this research before you attend or within 3 months of your screening visit, and your care will not be affected in any way. To opt-out, please visit our website at www.imperial.ac.uk/aiscreening, or call us on 0203 313 0147. If you opt-out after your screening visit, your data may have already been processed for the study. We will ensure that your data is removed from the study and confirm with you that this has happened.

This research is a collaboration between Imperial College London, St George's University Hospitals NHS Foundation Trust, Imperial College Healthcare NHS Trust, and Royal Surrey NHS Foundation Trust, with Google Health as the technology partner. Google Health's research group is exploring the use of artificial intelligence to assist in the screening and diagnosis of breast cancer. The UK's National Institute for Health Research (NIHR) has funded this research project to understand whether this technology can help the breast screening programme in the UK.

This study was reviewed by the Confidentiality Advisory Group (CAG). CAG is an independent group of lay people and professionals which provides expert advice on the use of confidential patient information without consent. CAG recommended that this study should be supported, and the Decision Maker within the Health Research Authority approved this.

We have put together a short video that explains both how the study will run and the role of the technology in the future. You can watch this video on our website.

For more information about the study and how your data will be used, a copy of a detailed information leaflet is available at the screening site, or please visit our website using the QR code or link: www.imperial.ac.uk/aiscreening



Key study information

Study sponsor: Imperial College London

Study funder: National Institute for Health Research

Chief Investigator: Professor Ara Darzi, Institute of Global Health Innovation, Imperial College London, 10th Floor, Queen Elizabeth the Queen Mother Wing, St. Mary's, London, W2 1NY

Email: aimstrial@imperial.ac.uk

Visit our website <u>www.imperial.ac.uk/aiscreening</u> or your screening site for a translated version of this leaflet. Available in Polish, Portuguese, Spanish, Italian, Turkish, Tamil, Gujarati, Punjabi, Hindi, Urdu, Arabic, Korean, Cantonese, Mandarin